ALIANNA GILMARTIN: Open Payments
NPI 1730639089 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,193 in 62 payments from 18 companies in 2025. Trend: 2023 $984 · 2024 $850 · 2025 $1,193
Food & beverage: $1,193
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $304 |
| AstraZeneca Pharmaceuticals LP | 5 | $172 |
| Lilly USA, LLC | 10 | $148 |
| Gilead Sciences, Inc. | 7 | $132 |
| Novo Nordisk Inc | 5 | $101 |
| GlaxoSmithKline, LLC. | 3 | $44 |
| Amgen Inc. | 3 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Dexcom, Inc. | 1 | $34 |
| PFIZER INC. | 2 | $32 |
Products named: AIRSUPRA, MOUNJARO, QULIPTA, MAVYRET, VRAYLAR, Repatha, Rybelsus, Ozempic.
Industry payments across FL — which companies pay providers there.
